Zensar’s life sciences acquisition bridges capability gaps to accelerate growth

Zensar Technologies has served healthcare and life science clients for 25 years. In January 2023, it officially established a healthcare and life science business unit as its go-to-market (GTM), which has become its fastest-growing business unit. The revised GTM has helped identify gaps in pharmaceutical commercialization, product launches, and niche markets such as rare diseases. To stand out in a competitive market dominated by larger service providers, Zensar needed to enhance its domain expertise and commercialization capabilities. It needed to move toward specialized solutions rather than generic IT solutions, targeting mid-sized firms. The acquisition of BridgeView Life Sciences provides Zensar with a competitive edge in delivering solutions throughout the life science value chain from R&D to product commercialization.

BridgeView enhances pharma commercialization and advisory expertise

Zensar’s acquisition of BridgeView Life Sciences marks a strategic expansion of its capabilities to address opportunities in the life sciences segment. BridgeView’s expertise in commercial pharma solutions and strong partnerships with key players such as Veeva and Salesforce help Zensar offer end-to-end services while broadening its footprint in the US market. It also enhances operational scalability, leveraging India-based teams for global delivery. In addition to technology solutions, BridgeView supports firms through advisory roles such as fractional CXO services and comprehensive project management offices (PMO). This model mainly works across biotech firms, which often lack these capabilities.

For Zensar, integrating BridgeView is a force multiplier, boosting scale and expertise in life sciences (see Exhibit 1). BridgeView, while integrated into Zensar’s broader ecosystem, retains its independent identity. This dual model ensures clients benefit from the agility and personalized service of a boutique consultancy supported by the scalability of a global technology firm with more than 10,000 employees and 30 offices worldwide.

Exhibit 1: Zensar’s broadened capabilities with BridgeView’s expertise

Source: HFS Research, 2024

Tailored solutions by Bridgeview drive measurable outcomes

Enterprises partnering with Zensar gain specialized expertise in life sciences coupled with global operational scalability. This enables faster time-to-market for therapies and streamlines commercialization efforts.

BridgeView helps its clients overcome operational challenges by delivering customized solutions across various industries. Examples include:

• Biotech: Developed a commercial roadmap incorporating customer relationship management (CRM) and analytics tools, enabling a successful US drug launch with more than 6 years of scalable growth. BridgeView continues to support the firm for global expansions, new product launches, and the deployment of additional technologies.
• Pharmaceutical: Leveraged real-time data and identified critical patient journey points, resulting in faster authorizations, higher shipment rates, fewer withdrawals, and increased repeat prescribers, ultimately improving patient outcomes and operational efficiency.
• Technology: Implemented consistent IT project management office (PMO) processes leveraging industry expertise, documentation templates, technology solutions, and elastic resourcing. Key outcomes included on-time, on-budget delivery, meeting objectives, mitigating risks and disruption, and driving adoption of corporate initiatives.

The Bottom Line: Segment-specific acquisitions are key to bridging capability gaps and accelerating value creation.

Zensar’s acquisition of BridgeView Life Sciences showcases the power of targeted acquisitions in bridging capability gaps and enabling faster value delivery in complex markets such as life sciences. With BridgeView’s expertise and Zensar’s global reach, Zensar can be a go-to partner for healthcare enterprises navigating regulatory landscapes, product launches, and operational scalability. Enterprises wanting to address capability gaps and accelerate value creation should:

• Focus on capability-driven acquisitions: Evaluate where targeted acquisitions could add specialized expertise and accelerate time-to-market outcomes.
• Align with market-specific strategies: Keep acquisitions distinct to preserve their operational strengths while aligning back-office functions for efficiency.